E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. (November 2020)

• Record Type: Journal Article
• Authors: Armangue, Thaís; Capobianco, Marco; de Chalus, Aliénor; Laetitia, Giorgi; Deiva, Kumaran; Bruijstens, Arlette L.; Wendel, Eva-Maria; Lechner, Christian; Bartels, Frederik; Finke, Carsten; Breu, Markus; Flet-Berliac, Lorraine; Adamsbaum, Catherine; Hacohen, Yael; Hemingway, Cheryl; Wassmer, Evangeline; Lim, Ming; Baumann, Matthias; Wickström, Ronny; Rostasy, Kevin; Neuteboom, Rinze F.
• Is Part Of: European journal of paediatric neurology. Volume 29(2020)
• Page Start: 22
• Page End: 31
• Publication Date: 2020-11
• Subjects: Myelin-oligodendrocyte glycoprotein -- Acquired demyelinating syndromes -- Children -- Cell based assays -- Biomarkers -- Neurofilament; ADEM acute disseminated encephalomyelitis -- ADS acquired demyelinating syndromes -- Anti-DC-ASGPR anti-dendritic cell-asialoglycoprotein receptor -- APC antigen presenting cells -- AQP4 aquaporin 4 -- BBB blood brain barrier -- CBA cell-based assays -- CNS central nervous system -- CSF cerebrospinal fluid -- EAE experimental autoimmune encephalomyelitis -- EDSS Expanded Disability Status Scale -- FACS flow cytometry -- Fc constant region -- IF immunofluorescence -- G-CSF granulocyte-colony stimulating factor -- GFAP glial fibrillary acidic protein -- GM-CSF granulocyte-macrophage-colony stimulating factor -- Ig immunoglobulin -- LETM longitudinally extensive myelitis -- MBP myelin basic protein -- MHC-II major histocompatibility complex class II -- MOG myelin oligodendrocyte glycoprotein -- MOG-abs: MOG antibodies MOGAD -- myelin oligodendrocyte glycoprotein antibody associated disorders MS -- multiple sclerosis Nfl: neurofilament light chain -- NHP Non human primate model -- NMDAR N-methyl-d-aspartate receptor -- NMOSD neuromyelitis optica spectrum disorders -- OCB oligoclonal bands -- ON optic neuritis -- rh-MOG recombinant human MOG -- VCAM-1 vascular cell-adhesion molecule 1; Pediatric neurology -- Periodicals; Nervous System Diseases -- Periodicals; Child -- Periodicals; Infant -- Periodicals; Neurologie pédiatrique -- Périodiques; Pediatric neurology; Electronic journals; Periodicals; Electronic journals; 618.928
• DOI: 10.1016/j.ejpn.2020.11.001
• Languages: English
• ISSNs: 1090-3798

Abstract

Abstract: A first episode of acquired demyelinating disorder (ADS) in children is a diagnostic challenge as different diseases can express similar clinical features. Recently, antibodies against myelin oligodendrocyte glycoprotein (MOG) have emerged as a new ADS biomarker, which clearly allow the identification of monophasic and relapsing ADS forms different from MS predominantly in children. Due to the novelty of this antibody there are still challenges and controversies about its pathogenicity and best technique to detect it. In this manuscript we will discuss the recommendations and caveats on MOG antibody assays, role in the pathogenesis, and additionally discuss the usefulness of other potential new biomarkers in MOG-antibody associated disorders (MOGAD). Highlights: Cell based assays with serum are the test of choice for MOG antibody testing. Serial testing of MOG antibodies can give information about risk of relapses. Recent data from animal models suggest that MOG antibodies are pathogenic. OCB have a high positive predictive value for the diagnosis of MS but not MOGAD. New biomarkers may help to monitor disease activity in MOGAD in the future.